Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH

Related Experiment Video

Updated: Aug 25, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Han Bok Kwak1, Soo Woong Lee, Yin-Ji Li

  • 1Department of Chemistry, Division of Molecular Life Science, Ewha Womans University, Seoul 120-750, South Korea.

Biochemical Pharmacology
|March 12, 2004
PubMed

Insights

The organic compound SCOH effectively inhibits osteoclast differentiation and activity. This phosphatidylcholine derivative shows promise for treating bone resorption diseases by targeting key cellular pathways.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Pharmacology

Background:

  • Osteoclasts are crucial multinucleated cells derived from hematopoietic progenitors.
  • Dysregulated osteoclast activity underlies various bone diseases, making them therapeutic targets.
  • Intervening in osteoclast differentiation offers a potential treatment strategy for bone disorders.

Purpose of the Study:

  • To investigate the effects of the organic compound (S)-1-lyso-2-stearoylamino-2-deoxy-sn-glycero-3-phosphatidylcholine (SCOH) on osteoclast differentiation and function.
  • To determine the molecular mechanisms by which SCOH impacts osteoclastogenesis and activity.

Main Methods:

  • Osteoclast differentiation was induced in mouse bone marrow cell cultures with M-CSF and RANKL, or co-cultured with osteoblasts.
  • The effects of SCOH on cell differentiation, signaling pathways (ERK, Akt, NF-kappaB), bone resorption, actin ring formation, and osteoclast survival were assessed.
  • Changes in XIAP induction in mature osteoclasts treated with SCOH were analyzed.

Main Results:

  • SCOH significantly inhibited osteoclast differentiation induced by M-CSF/RANKL or osteoblast co-culture.
  • SCOH suppressed the activation of ERK, Akt, and NF-kappaB signaling pathways during osteoclast differentiation.
  • SCOH attenuated bone resorption, actin ring formation, and survival of mature osteoclasts, with reduced Akt/NF-kappaB activation and XIAP induction.

Conclusions:

  • The novel phosphatidylcholine derivative SCOH demonstrates potent inhibitory effects on osteoclast differentiation and activity.
  • SCOH targets key signaling pathways involved in osteoclastogenesis and function.
  • SCOH holds potential as a therapeutic agent for managing bone resorption diseases.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.